SCHEMBL24549259

SCHEMBL24549259

Clc1cc(Nc2nc3ccc(C4CCC4)cc3[nH]2)cc2[nH]ccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 3/20 0.50
▸ SYK P43405 1/20 0.39
▸ KCNH2 Q12809 1/20 0.39
▸ RIPK1 Q13546 2/20 0.38
▸ KDR P35968 4/20 0.38
▸ POLB P06746 1/20 0.36
▸ CSNK1A1 P48729 2/20 0.34
▸ CSNK1D P48730 2/20 0.34
▸ GSK3B P49841 2/20 0.34
▸ CSNK1G2 P78368 2/20 0.34
▸ KCNN1 Q92952 1/20 0.34
▸ KCNN2 Q9H2S1 1/20 0.34
▸ KCNN3 Q9UGI6 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24549239 0.89 BTK (0.42) BTKSYKRIPK1KDRKCNN1
SCHEMBL24549228 0.84 SYK (0.38) BTKSYKKCNH2KDRPOLB
SCHEMBL24549235 0.83 SYK (0.38) BTKSYKKCNH2KDRCSNK1A1
SCHEMBL29653718 0.82 SYK (0.37) BTKSYKKCNH2KDRKCNN1
SCHEMBL24549464 0.82 SYK (0.37) BTKSYKKCNH2KDRKCNN1
SCHEMBL30750865 0.82 PRKAB2 (0.39) BTKSYKKCNN1KCNN2KCNN3
SCHEMBL24549466 0.82 PRKAB2 (0.39) BTKSYKKCNN1KCNN2KCNN3
SCHEMBL24549232 0.81 KCNH2 (0.44) BTKSYKKCNH2KDR
SCHEMBL24548986 0.81 SYK (0.37) BTKSYKKCNH2KDR
SCHEMBL24548979 0.81 SYK (0.36) BTKSYKKCNH2KDRCSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240051970-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2024-02-15 — — US disclosed
CN-117321048-A Compounds and compositions for the treatment of diseases associated with STING activity 艾福姆德尤股份有限公司 2023-12-29 — — CN disclosed
WO-2022133098-A2 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2022-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240051970-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 BTK 255/4885SYK 727/4885KCNH2 2622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback